BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
BRIEF: Innogen launches $87 million Hong Kong IPO
Guangzhou Innogen Pharmaceutical Group Co. Ltd. (6603.HK) launched its Hong Kong IPO on Thursday, aiming to sell 36.56 million shares for HK$18.68 apiece to raise about HK$683 million ($87 million).…
BRIEF: Leads Biolab nearly doubles in Hong Kong trading debut
Shares of Nanjing Leads Biolab Co. Ltd. (9887.HK) rose 91.7% to close at HK$67.10 on their first trading day on Friday, after the company sold 36.86 million shares for HK$35 each,…
BRIEF: Cloudbreak tumbles in Hong Kong trading debut
Ophthalmic biotech company Cloudbreak Pharma Inc. (2592.HK) opened down 6% in its Hong Kong trading debut on Wednesday, and continued to fall during the morning session to close down 30% at HK$7.04…
BRIEF: Cloudbreak launches $78 million Hong Kong IPO
Ophthalmic biotech company Cloudbreak Pharma Inc. (2592.HK) launched its Hong Kong IPO on Tuesday, aiming to sell 60.58 million shares at HK$10.10 apiece to raise about HK$610 million ($78 million). Share…
BRIEF: Green Economy invests $1.48 million in Bayed Health Group IPO
Building maintenance services company Green Economy Development Ltd. (1315.HK) said on Wednesday it will invest HK$11.6 million ($1.48 million) in shares of Bayzed Health Group Inc. (2609.HK) during the biotech…